{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:55:14Z","timestamp":1794243314348,"version":"4.9.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lipids play essential roles in the hepatitis C virus (HCV) life cycle and patients with chronic HCV infection display disordered lipid metabolism which resolves following successful anti-viral therapy. It has been proposed that HCV genotype 3 (HCV-G3) infection is an independent risk factor for hepatocellular carcinoma and evidence suggests lipogenic proteins are involved in hepatocarcinogenesis. We aimed to characterise variation in host lipid metabolism between participants chronically infected with HCV genotype 1 (HCV-G1) and HCV-G3 to identify likely genotype-specific differences in lipid metabolism. We combined several lipidomic approaches: analysis was performed between participants infected with HCV-G1 and HCV-G3, both in the fasting and non-fasting states, and after sustained virological response (SVR) to treatment. Sera were obtained from 112 fasting patients (25% with cirrhosis). Serum lipids were measured using standard enzymatic methods. Lathosterol and desmosterol were measured by gas-chromatography mass spectrometry (MS). For further metabolic insight on lipid metabolism, ultra-performance liquid chromatography MS was performed on all samples. A subgroup of 13 participants had whole body fat distribution determined using in vivo magnetic resonance imaging and spectroscopy. A second cohort of (non-fasting) sera were obtained from HCV Research UK for comparative analyses: 150 treatment na\u00efve patients and 100 non-viraemic patients post-SVR. HCV-G3 patients had significantly decreased serum apoB, non-HDL cholesterol concentrations, and more hepatic steatosis than those with HCV-G1. HCV-G3 patients also had significantly decreased serum levels of lathosterol, without significant reductions in desmosterol. Lipidomic analysis showed lipid species associated with reverse cholesterol transport pathway in HCV-G3. We demonstrated that compared to HCV-G1, HCV-G3 infection is characterised by low LDL cholesterol levels, with preferential suppression of cholesterol synthesis via lathosterol, associated with increasing hepatic steatosis. The genotype-specific lipid disturbances may shed light on genotypic variations in liver disease progression and promotion of hepatocellular cancer in HCV-G3.<\/jats:p>","DOI":"10.1038\/s41598-022-09588-w","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:50:08Z","timestamp":1648821008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis"],"prefix":"10.1038","volume":"12","author":[{"given":"David A.","family":"Sheridan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Thom","family":"Shawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Louise","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Felmlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon H.","family":"Bridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dermot","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy F.","family":"Cobbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret F.","family":"Bassendine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.","family":"Taylor-Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"issue":"6","key":"9588_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.tem.2011.03.004","volume":"22","author":"E Herker","year":"2011","unstructured":"Herker, E. & Ott, M. Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol. Metab. 22(6), 241\u2013248 (2011).","journal-title":"Trends Endocrinol. Metab."},{"issue":"6","key":"9588_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.jhep.2011.06.004","volume":"55","author":"MF Bassendine","year":"2011","unstructured":"Bassendine, M. F. et al. HCV and the hepatic lipid pathway as a potential treatment target. J. Hepatol. 55(6), 1428\u20131440 (2011).","journal-title":"J. Hepatol."},{"key":"9588_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhep.2008.03.016","volume":"49","author":"CY Dai","year":"2008","unstructured":"Dai, C. Y. et al. Associations between hepatitis C viraemia and low serum triglyceride and cholesterol levels: A community-based study. J. Hepatol. 49, 9\u201316 (2008).","journal-title":"J. Hepatol."},{"key":"9588_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0168-8278(00)00036-2","volume":"34","author":"L Serfaty","year":"2001","unstructured":"Serfaty, L. et al. Hepatitis C induced hypobetalipoproteinaemia; a possible mechanism for steatosis in chronic hepatitis C. J. Hepatol. 34, 428\u2013434 (2001).","journal-title":"J. Hepatol."},{"key":"9588_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-2893.2005.00655.x","volume":"13","author":"D Siagris","year":"2006","unstructured":"Siagris, D. et al. Serum lipid pattern in chronic hepatitis C: Histological and virological correlations. J. Viral Hepatitis 13, 56\u201361 (2006).","journal-title":"J. Viral Hepatitis"},{"issue":"4","key":"9588_CR6","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/hep.23219","volume":"50","author":"KE Corey","year":"2009","unstructured":"Corey, K. E. et al. Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up. Hepatology 50(4), 1030\u20131037 (2009).","journal-title":"Hepatology"},{"issue":"12","key":"9588_CR7","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1365-2036.2009.04012.x","volume":"29","author":"DA Sheridan","year":"2009","unstructured":"Sheridan, D. A. et al. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol. Ther. 29(12), 1282\u20131290 (2009).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"10","key":"9588_CR8","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/jmv.21850","volume":"82","author":"C Larsen","year":"2010","unstructured":"Larsen, C. & Committee HCVSS et al. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J. Med. Virol. 82(10), 1647\u20131654 (2010).","journal-title":"J. Med. Virol."},{"issue":"3","key":"9588_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.cgh.2016.10.012","volume":"15","author":"BJ McMahon","year":"2017","unstructured":"McMahon, B. J. et al. Infection with hepatitis c virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma, and liver-related death. Clin. Gastroenterol. Hepatol. 15(3), 431\u2013437 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"9588_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.27095","volume":"60","author":"F Kanwal","year":"2014","unstructured":"Kanwal, F., Kramer, J. R., Ilyas, J., Duan, Z. & El-Serag, H. B. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 60(1), 98\u2013105 (2014).","journal-title":"Hepatology"},{"issue":"4","key":"9588_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/jvh.13047","volume":"26","author":"SS Lee","year":"2019","unstructured":"Lee, S. S. et al. Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea. J. Viral Hepat. 26(4), 459\u2013465 (2019).","journal-title":"J. Viral Hepat."},{"key":"9588_CR12","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3389\/fonc.2019.01412","volume":"9","author":"L Che","year":"2019","unstructured":"Che, L. et al. Pathogenetic, prognostic, and therapeutic role of fatty acid synthase in human hepatocellular carcinoma. Front Oncol. 9, 1412 (2019).","journal-title":"Front Oncol."},{"issue":"4","key":"9588_CR13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jhep.2014.11.016","volume":"62","author":"SH Bridge","year":"2015","unstructured":"Bridge, S. H. et al. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism. J. Hepatol. 62(4), 763\u2013770 (2015).","journal-title":"J. Hepatol."},{"issue":"4","key":"9588_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1194\/jlr.P800042-JLR200","volume":"50","author":"TM van Himbergen","year":"2009","unstructured":"van Himbergen, T. M. et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J. Lipid Res. 50(4), 730\u2013739 (2009).","journal-title":"J. Lipid Res."},{"issue":"1","key":"9588_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/oxfordjournals.aje.a115479","volume":"131","author":"TA Miettinen","year":"1990","unstructured":"Miettinen, T. A., Tilvis, R. S. & Kesaniemi, Y. A. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am. J. Epidemiol. 131(1), 20\u201331 (1990).","journal-title":"Am. J. Epidemiol."},{"key":"9588_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.plipres.2019.02.003","volume":"74","author":"J Plat","year":"2019","unstructured":"Plat, J. et al. Plant-based sterols and stanols in health & disease: \u201cConsequences of human development in a plant-based environment?\u201d. Prog. Lipid Res. 74, 87\u2013102 (2019).","journal-title":"Prog. Lipid Res."},{"issue":"4","key":"9588_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0168-8278(96)80165-6","volume":"24","author":"H Gylling","year":"1996","unstructured":"Gylling, H., Vuoristo, M., Farkkila, M. & Miettinen, T. A. The metabolism of cholestanol in primary biliary cirrhosis. J. Hepatol. 24(4), 444\u2013451 (1996).","journal-title":"J. Hepatol."},{"issue":"2","key":"9588_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrm2336","volume":"9","author":"E Ikonen","year":"2008","unstructured":"Ikonen, E. Cellular cholesterol trafficking and compartmentalization. Nat. Rev. Mol. Cell Biol. 9(2), 125\u2013138 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"9588_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0009-8981(95)06038-4","volume":"236","author":"RI Kelley","year":"1995","unstructured":"Kelley, R. I. Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography\/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts. Clin. Chim. Acta. 236(1), 45\u201358 (1995).","journal-title":"Clin. Chim. Acta."},{"issue":"1","key":"9588_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/oby.2011.142","volume":"20","author":"EL Thomas","year":"2012","unstructured":"Thomas, E. L. et al. The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat. Obesity (Silver Spring) 20(1), 76\u201387 (2012).","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"9588_CR21","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1021\/ac500317c","volume":"86","author":"MH Sarafian","year":"2014","unstructured":"Sarafian, M. H. et al. Objective set of criteria for optimization of sample preparation procedures for ultra-high throughput untargeted blood plasma lipid profiling by ultra performance liquid chromatography-mass spectrometry. Anal. Chem. 86(12), 5766\u20135774 (2014).","journal-title":"Anal. Chem."},{"issue":"15","key":"9588_CR22","doi-asserted-by":"publisher","first-page":"6869","DOI":"10.1021\/ac301482k","volume":"84","author":"M Eliasson","year":"2012","unstructured":"Eliasson, M. et al. Strategy for optimizing LC-MS data processing in metabolomics: A design of experiments approach. Anal. Chem. 84(15), 6869\u20136876 (2012).","journal-title":"Anal. Chem."},{"issue":"6","key":"9588_CR23","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1053\/j.gastro.2006.02.035","volume":"130","author":"S Mirandola","year":"2006","unstructured":"Mirandola, S. et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130(6), 1661\u20131669 (2006).","journal-title":"Gastroenterology"},{"issue":"5","key":"9588_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/cells8050512","volume":"8","author":"N Berndt","year":"2019","unstructured":"Berndt, N. et al. Characterization of lipid and lipid droplet metabolism in human HCC. Cells 8(5), 512 (2019).","journal-title":"Cells"},{"issue":"12","key":"9588_CR25","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1002\/cncr.11427","volume":"97","author":"K Ohata","year":"2003","unstructured":"Ohata, K. et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 97(12), 3036\u20133043 (2003).","journal-title":"Cancer"},{"key":"9588_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/hep.25631","volume":"56","author":"PJ Clark","year":"2012","unstructured":"Clark, P. J. et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 56, 49\u201356 (2012).","journal-title":"Hepatology"},{"issue":"1","key":"9588_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jhep.2015.08.027","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. J. Hepatol. 64(1), 29\u201336 (2016).","journal-title":"J. Hepatol."},{"key":"9588_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/hep.25631","volume":"56","author":"P Clark","year":"2012","unstructured":"Clark, P. et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype specific manner. Hepatology 56, 49\u201356 (2012).","journal-title":"Hepatology"},{"issue":"4","key":"9588_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1665-2681(19)31166-4","volume":"14","author":"L Melo-Villar","year":"2015","unstructured":"Melo-Villar, L. et al. Hypovitaminosis D and its relation to demographic and laboratory data among hepatitis C patients. Ann. Hepatol. 14(4), 457\u2013463 (2015).","journal-title":"Ann. Hepatol."},{"issue":"12","key":"9588_CR30","doi-asserted-by":"publisher","first-page":"e115309","DOI":"10.1371\/journal.pone.0115309","volume":"9","author":"U Loizides-Mangold","year":"2014","unstructured":"Loizides-Mangold, U. et al. HCV 3a core protein increases lipid droplet cholesteryl ester content via a mechanism dependent on sphingolipid biosynthesis. PLoS ONE 9(12), e115309 (2014).","journal-title":"PLoS ONE"},{"issue":"5","key":"9588_CR31","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1053\/j.gastro.2010.07.047","volume":"139","author":"DJ Felmlee","year":"2010","unstructured":"Felmlee, D. J. et al. Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles. Gastroenterology 139(5), 1774\u20131783 (2010).","journal-title":"Gastroenterology"},{"issue":"5","key":"9588_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.plipres.2008.03.003","volume":"47","author":"L Hodson","year":"2008","unstructured":"Hodson, L., Skeaff, C. M. & Fielding, B. A. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog. Lipid Res. 47(5), 348\u2013380 (2008).","journal-title":"Prog. Lipid Res."},{"issue":"5","key":"9588_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4254\/wjh.v8.i5.291","volume":"8","author":"K Satoh","year":"2016","unstructured":"Satoh, K. et al. High level of serum cholesteryl ester transfer protein in active hepatitis C virus infection. World J. Hepatol. 8(5), 291\u2013300 (2016).","journal-title":"World J. Hepatol."},{"issue":"8","key":"9588_CR34","doi-asserted-by":"publisher","first-page":"e23641","DOI":"10.1371\/journal.pone.0023641","volume":"6","author":"B Roe","year":"2011","unstructured":"Roe, B., Kensicki, E., Mohney, R. & Hall, W. W. Metabolomic profile of hepatitis C virus-infected hepatocytes. PLoS ONE 6(8), e23641 (2011).","journal-title":"PLoS ONE"},{"issue":"12","key":"9588_CR35","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1172\/JCI30163","volume":"116","author":"DJ Rader","year":"2006","unstructured":"Rader, D. J. Molecular regulation of HDL metabolism and function: Implications for novel therapies. J. Clin. Investig. 116(12), 3090\u20133100 (2006).","journal-title":"J. Clin. Investig."},{"issue":"43","key":"9588_CR36","doi-asserted-by":"publisher","first-page":"41624","DOI":"10.1074\/jbc.M305289200","volume":"278","author":"B Bartosch","year":"2003","unstructured":"Bartosch, B. et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278(43), 41624\u201341630 (2003).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"9588_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1128\/JVI.01134-06","volume":"81","author":"SB Kapadia","year":"2007","unstructured":"Kapadia, S. B., Barth, H., Baumert, T., McKeating, J. A. & Chisari, F. V. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J. Virol. 81(1), 374\u2013383 (2007).","journal-title":"J. Virol."},{"issue":"5","key":"9588_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000341688","volume":"30","author":"S Buhler","year":"2012","unstructured":"Buhler, S. & Bartenschlager, R. Promotion of hepatocellular carcinoma by hepatitis C virus. Dig. Dis. 30(5), 445\u2013452 (2012).","journal-title":"Dig. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09588-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09588-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09588-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T20:16:33Z","timestamp":1669320993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09588-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9588"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-09588-w","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/FOIC1P","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5562"}}